{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-216744","form_type":"8-K","ticker":"EIKN","cik":"0001861123","company_name":"Eikon Therapeutics, Inc.","filed_at":"2026-05-11T20:05:32+00:00","discovered_at":"2026-05-11T20:07:00.351027+00:00","generated_at":"2026-05-11T22:49:23.548014+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Eikon Therapeutics Q1 2026 net loss $83M, cash $596M; three oncology programs advance","bullets":["Net loss $83M (Q1 2026) vs $74.5M (Q1 2025); R&D expenses $70M (+24%) incl. $5M milestone to Impact Therapeutics.","Cash, equivalents and marketable securities $596M at March 31, 2026; expected to fund operations into H2 2027.","EIK1001: Phase 2 NSCLC trial fully enrolled; updated data at ASCO; Phase 2/3 trials in melanoma and NSCLC initiated.","EIK1003: Dose escalation completed; Phase 2 dose optimization trial first patient dosed; global site selection for Cohort 1D started.","EIK1005 (WRN helicase inhibitor): Phase 1/2 trial began dosing Feb 2026; two abstracts accepted for ASCO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-216744","json":"https://secwatch.observer/filing/0001193125-26-216744.json","markdown":"https://secwatch.observer/filing/0001193125-26-216744.md","text":"https://secwatch.observer/filing/0001193125-26-216744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526216744/0001193125-26-216744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526216744/eikn-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:49:23.548014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c107f75c3a169c8289bfb0b1317c13dad7955706","claim":"Eikon Therapeutics, Inc. reported first quarter 2026 results: net income $83.0 million.","evidence_excerpt":"Net loss attributable to common stockholders was $83.0 million for the first quarter of 2026, as compared to $74.5 million for the prior-year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526216744/0001193125-26-216744-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2026"},{"label":"Net income","value":"$83.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}